• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, October 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

The structure of protein RAF1 revealed: a key step in the development of new drugs against lung cancer

Bioengineer by Bioengineer
September 1, 2022
in Health
Reading Time: 3 mins read
0
CNIO scientists: Sara García Alonso and Laura De la Puente
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

One of the main challenges in oncology is the development of drugs against KRAS oncogenes. These oncogenes -genes that cause cancer when mutated – are responsible for a quarter of all human cancers, including the three tumor types with the highest mortality rates: lung adenocarcinoma, colorectal carcinoma and pancreatic ductal adenocarcinoma.

CNIO scientists: Sara García Alonso and Laura De la Puente

Credit: CNIO

One of the main challenges in oncology is the development of drugs against KRAS oncogenes. These oncogenes -genes that cause cancer when mutated – are responsible for a quarter of all human cancers, including the three tumor types with the highest mortality rates: lung adenocarcinoma, colorectal carcinoma and pancreatic ductal adenocarcinoma.

Although KRAS oncogenes were already discovered by Mariano Barbacid’s group four decades ago, the first drug against them -Sotorasib, Amgen- has been approved by the FDA only a year ago. As important as this milestone is, Sotorasib acts only against tumors carrying one of the multiple mutations present in the KRAS oncogenes and its clinical impact is therefore limited. Moreover, patients treated with this drug develop resistance within a few months of treatment. 

 

RAF1 and lung adenocarcinoma

Beyond the development of drugs against KRAS, one of the most active research areas at the moment seeks to identify inhibitors of proteins, such as RAF1, responsible for transmitting the KRAS oncogenic signals. 

In this regard, Mariano Barbacid’s laboratory, using genetically modified mouse models that faithfully recapitulate human lung adenocarcinomas, demonstrated four years ago that elimination of the RAF1 protein induced regression of most tumors without significant toxic effects.

Target: degrading RAF1

These observations have generated enormous interest in finding drugs capable of degrading RAF1. The results published today in Molecular Cell open up a window of opportunity to design RAF1 degraders that, either alone or in combination with KRAS inhibitors, could generate an important therapeutic effect in patients with lung adenocarcinoma induced by KRAS oncogenes.

The determination of the three-dimensional structure of RAF1 is a key step towards this goal, because it reveals the parts of the protein to which a drug could be chemically anchored, and promote its destruction by the cellular machinery (cells have cleaning mechanisms that degrade defective or useless proteins). 

The main researchers responsible for this work are Sara García-Alonso, from the CNIO, and Pablo Mesa, from the Molecular and Structural Biology group at the University of Copenhagen.

“The information provided by this study opens up a range of options for developing drugs that can degrade RAF1,” says García-Alonso. “A window of opportunity is now open to design RAF1 degraders with an important therapeutic effect in patients with lung adenocarcinoma induced by KRAS oncogenes.” 

 

Funding

Barbacid’s group has been funded mainly by the CRIS Against Cancer Foundation, the Spanish Association Against Cancer (AECC) and the AXA Research Fund, as well as by public funds from the Spanish Ministry of Science and the European Research Council (ERC). Sara García-Alonso currently enjoys a postdoctoral contract from the AECC.



Journal

Molecular Cell

DOI

10.1016/j.molcel.2022.08.012

Share12Tweet8Share2ShareShareShare2

Related Posts

Spin Squeezing Achieved in Diamond NV Centers

October 2, 2025

Spirituality Eases Occupational Stress in Nurses’ Lives

October 2, 2025

Hashimoto’s Thyroiditis: CA 19-9 and CA 72-4 Levels

October 2, 2025

Danshen Ligustrazine Injection: Impact on Hypertension Biomarkers

October 2, 2025

POPULAR NEWS

  • New Study Reveals the Science Behind Exercise and Weight Loss

    New Study Reveals the Science Behind Exercise and Weight Loss

    91 shares
    Share 36 Tweet 23
  • Physicists Develop Visible Time Crystal for the First Time

    74 shares
    Share 30 Tweet 19
  • New Study Indicates Children’s Risk of Long COVID Could Double Following a Second Infection – The Lancet Infectious Diseases

    73 shares
    Share 29 Tweet 18
  • How Donor Human Milk Storage Impacts Gut Health in Preemies

    64 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Spin Squeezing Achieved in Diamond NV Centers

Revolutionizing Materials: Long-Distance Remote Epitaxy

Spirituality Eases Occupational Stress in Nurses’ Lives

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 60 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.